Bexarotene is a medicine used to treat a specific type of skin cancer called Cutaneous T-Cell Lymphoma. It works by blocking a protein that helps cancer cells grow. It's taken as a pill, usually once a day.
Every report comes from a Lived member, sent anonymously.
Have you tried Targretin (Bexarotene) for Cutaneous T-Cell Lymphoma?
Bexarotene, sold under the brand name Targretin and as a generic, is a prescription cancer medicine for cutaneous T-cell lymphoma (CTCL). CTCL is a rare lymphoma in which cancerous T cells, a type of white blood cell, collect in the skin and cause patches, thicker plaques or tumors. Mycosis fungoides is its most common form. Bexarotene capsules, taken by mouth, are approved to treat the skin manifestations of CTCL in people whose disease has not responded well enough to at least one earlier systemic (whole-body) treatment. A 1% gel version is approved for early-stage disease (stages IA and IB, limited to skin patches and plaques) when other treatments have not worked, have stopped working or were not tolerated. CTCL is usually a long-term condition, and bexarotene is used to control its skin effects; many people use several different treatments over the years.
Bexarotene is a retinoid, a medicine related to vitamin A. It belongs to a subgroup called rexinoids because it activates retinoid X receptors (RXRs), proteins inside cells that turn on genes controlling how cells mature and how quickly they multiply. In laboratory studies this slows the growth of some cancer cell types, but exactly why it helps CTCL is not known. The same receptors work in partnership with others involved in processing fats and in thyroid hormone signaling. That is a useful way to understand why the capsules' most common effects are on blood fats and the thyroid, and why treatment involves regular blood tests.
Bexarotene capsules (75 mg each) are taken once a day with a meal. The starting dose is calculated from body surface area, an estimate based on height and weight, so the number of capsules differs from person to person. The care team often lowers the dose or pauses treatment when side effects or blood test changes appear, and may raise it carefully if there has been no response after about eight weeks and the medicine is well tolerated. Treatment continues for as long as it is helping. The gel is applied in a generous layer to the lesions only. It is usually started every other day and increased week by week, up to as often as four times a day, depending on how the skin tolerates it. Let it dry before covering with clothing, keep it off the healthy skin around lesions and away from the eyes, mouth and other moist (mucous) surfaces, and do not cover treated areas with airtight dressings. For anyone who could become pregnant, either form is started on the second or third day of a normal period after a negative pregnancy test, and no more than a one-month supply is given at a time so that monthly testing can take place.
With the capsules, the most frequent change is one people cannot feel: large rises in triglycerides (a type of blood fat) and cholesterol, and a drop in HDL (high-density lipoprotein), the protective form of cholesterol. This happens in most people, usually within the first two to four weeks. Many people also develop an underactive thyroid (hypothyroidism), which shows up on blood tests and is often treated with thyroid hormone replacement. Headache, weakness and tiredness, rash, dry or peeling skin, itching, nausea, swelling of the legs, abdominal pain and infections are also common. Side effects are more frequent at higher doses. A few serious effects need prompt attention. Pancreatitis (inflammation of the pancreas) has occurred, mostly in people with very high triglycerides, and has rarely been fatal; contact the care team right away for nausea and vomiting with belly pain or back pain. Liver injury is uncommon but has led to liver failure, so report yellowing of the skin or eyes, loss of appetite, or unusual bleeding or bruising right away. Bexarotene can lower the white blood cells that fight infection, usually four to eight weeks after starting, so a fever or other signs of infection also call for a prompt call to the care team. New or worsening cataracts have been seen, so mention any change in vision. The gel mainly causes effects where it is applied: rash, itching, irritation and pain. These often settle when the gel is applied less often or paused for a few days.
Bexarotene can cause serious birth defects and must not be used during pregnancy; this applies to both the capsules and the gel. Anyone who could become pregnant needs a negative pregnancy test within a week before starting and every month during treatment. They should use two reliable forms of birth control at the same time (unless abstinent) from one month before starting until at least one month after stopping, and one of them should be non-hormonal, because bexarotene may make hormonal birth control less effective. Men taking bexarotene must use condoms with a partner who is or could become pregnant, during treatment and for at least one month afterward. If pregnancy occurs, stop the medicine and contact the care team immediately. Breastfeeding should stop during treatment, and people with a known serious allergy to bexarotene should not take it. Gemfibrozil, a triglyceride-lowering drug, raises bexarotene levels and should not be combined with the capsules; other lipid medicines, such as atorvastatin, are commonly used instead. People with diabetes who use insulin, a sulfonylurea (such as glipizide) or a thiazolidinedione (such as pioglitazone) may see their blood sugar drop lower than expected and should check it more often and report changes. Past pancreatitis, heavy drinking, poorly controlled diabetes or gallbladder disease raise the risk of pancreatitis, so the care team should know about them. Because bexarotene is related to vitamin A, avoid vitamin A supplements unless the care team approves them. It also makes skin more sensitive to sunlight and tanning lamps, so limit ultraviolet exposure. People using the gel should not use insect repellents containing DEET, a common repellent ingredient that was more toxic alongside bexarotene gel in animal testing.
Treatment with the capsules starts with blood work: fasting lipids, liver tests, thyroid tests and a complete blood count. Triglycerides need to be normal, or brought down, before the first dose. Lipids are then checked weekly for the first few weeks and liver tests at one, two and four weeks, and all of these continue at regular intervals (about every eight weeks once stable). Many people end up taking a lipid-lowering medicine and thyroid hormone alongside bexarotene. The aim is to keep fasting triglycerides below 400 mg/dL (milligrams per deciliter, the unit on the lab report) to lower the chance of pancreatitis. Most of these blood test changes reverse when the dose is reduced or the medicine is stopped. Skin improvement takes time. In the studies that led to approval, about three in ten people with hard-to-treat CTCL saw their measured skin lesions improve by at least half, while complete clearing was uncommon. Some responses appeared within four weeks and others later, and about three in ten of those who responded saw the disease worsen again during roughly five months of follow-up. With the gel, a response can appear at four weeks but usually takes longer. If bexarotene stops helping or its side effects cannot be managed, other CTCL treatments are available.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Targretin (Bexarotene), what you've noticed, or ask the community a question.